Marksans Pharma Ltd
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.
Our key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others. [1]
- Market Cap ₹ 13,312 Cr.
- Current Price ₹ 294
- High / Low ₹ 359 / 126
- Stock P/E 38.5
- Book Value ₹ 50.3
- Dividend Yield 0.20 %
- ROCE 20.6 %
- ROE 16.5 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Promoter holding has decreased over last 3 years: -4.38%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE Allcap BSE SmallCap BSE Healthcare Nifty Microcap 250 Nifty Total Market
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
438 | 630 | 797 | 893 | 767 | 913 | 1,000 | 1,134 | 1,376 | 1,491 | 1,852 | 2,177 | 2,379 | |
369 | 512 | 612 | 757 | 722 | 834 | 868 | 942 | 1,037 | 1,232 | 1,513 | 1,719 | 1,872 | |
Operating Profit | 69 | 118 | 185 | 136 | 45 | 78 | 132 | 192 | 340 | 259 | 340 | 459 | 507 |
OPM % | 16% | 19% | 23% | 15% | 6% | 9% | 13% | 17% | 25% | 17% | 18% | 21% | 21% |
4 | 4 | 3 | 9 | 7 | 8 | 5 | 0 | 7 | 42 | 59 | 50 | 47 | |
Interest | 15 | 19 | 16 | 10 | 7 | 10 | 10 | 9 | 8 | 8 | 9 | 11 | 14 |
Depreciation | 16 | 16 | 16 | 28 | 30 | 27 | 23 | 27 | 36 | 45 | 52 | 74 | 83 |
Profit before tax | 44 | 86 | 156 | 107 | 15 | 50 | 104 | 157 | 302 | 248 | 338 | 424 | 458 |
Tax % | -12% | 15% | 28% | 23% | 24% | 28% | 23% | 23% | 21% | 25% | 21% | 26% | |
49 | 74 | 112 | 83 | 11 | 36 | 80 | 121 | 239 | 187 | 265 | 315 | 347 | |
EPS in Rs | 1.19 | 1.87 | 2.67 | 1.92 | 0.22 | 0.80 | 1.87 | 2.95 | 5.76 | 4.51 | 5.88 | 6.92 | 7.66 |
Dividend Payout % | 10% | 5% | 4% | 21% | 23% | 6% | 3% | 3% | 4% | 6% | 9% | 9% |
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 17% |
3 Years: | 17% |
TTM: | 19% |
Compounded Profit Growth | |
---|---|
10 Years: | 16% |
5 Years: | 33% |
3 Years: | 10% |
TTM: | 17% |
Stock Price CAGR | |
---|---|
10 Years: | 17% |
5 Years: | 79% |
3 Years: | 73% |
1 Year: | 84% |
Return on Equity | |
---|---|
10 Years: | 18% |
5 Years: | 19% |
3 Years: | 17% |
Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 39 | 39 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 45 | 45 | 45 |
Reserves | 34 | 90 | 326 | 401 | 392 | 430 | 502 | 595 | 846 | 1,161 | 1,700 | 2,020 | 2,236 |
176 | 173 | 101 | 100 | 110 | 118 | 100 | 30 | 34 | 111 | 123 | 244 | 198 | |
152 | 188 | 207 | 180 | 209 | 142 | 160 | 236 | 307 | 323 | 322 | 372 | 432 | |
Total Liabilities | 401 | 490 | 676 | 722 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 2,190 | 2,681 | 2,911 |
156 | 146 | 166 | 270 | 267 | 279 | 270 | 303 | 309 | 428 | 486 | 776 | 787 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 3 | 10 | 9 | 11 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 27 | 15 |
245 | 344 | 510 | 452 | 484 | 451 | 533 | 599 | 907 | 1,205 | 1,694 | 1,869 | 2,098 | |
Total Assets | 401 | 490 | 676 | 722 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 2,190 | 2,681 | 2,911 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
39 | 65 | 155 | 31 | 14 | 50 | 27 | 233 | 179 | 99 | 237 | 230 | |
-5 | -4 | -33 | -123 | -21 | -39 | -13 | -60 | -45 | -84 | -259 | -141 | |
-40 | -29 | 17 | -58 | -3 | 3 | -21 | -114 | -15 | 80 | 198 | -69 | |
Net Cash Flow | -7 | 31 | 138 | -150 | -10 | 15 | -7 | 60 | 118 | 94 | 176 | 21 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 109 | 98 | 84 | 89 | 118 | 71 | 64 | 78 | 72 | 97 | 82 | 76 |
Inventory Days | 112 | 102 | 107 | 120 | 151 | 152 | 215 | 155 | 248 | 216 | 192 | 217 |
Days Payable | 81 | 83 | 88 | 85 | 129 | 54 | 78 | 71 | 103 | 102 | 91 | 94 |
Cash Conversion Cycle | 141 | 118 | 103 | 124 | 140 | 169 | 202 | 163 | 217 | 211 | 183 | 199 |
Working Capital Days | 37 | 48 | 55 | 95 | 130 | 117 | 133 | 94 | 110 | 138 | 133 | 138 |
ROCE % | 43% | 37% | 44% | 23% | 4% | 10% | 18% | 25% | 38% | 23% | 22% | 21% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 Dec
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
25 Nov - Marksans Pharma Q2 FY25 earnings and strategy update.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
22 Nov - Marksans Pharma receives USFDA approval for Loratadine Tablets.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
13 Nov - Audio recording of Q2&H1FY25 financial results call uploaded.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Nov
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT REC
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Feb 2021Transcript PPT
-
Nov 2020TranscriptNotesPPT
-
Aug 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
Revenue Mix
Revenue Mix by therapeutic wise FY23[1]
Pain Management : 44%
Cough & Cold : 14%
Cardiovascular System : 9%
CNS: 8%
Anti-diabetic : 2%
Gastrointestinal : 9%
Others : 14%